Prostate
- Home
- Cancer Infomation
Prostate Adenocarcinoma
Prostate adenocarcinoma accounts for the vast majority of prostate malignancies, typically originating in the glandular cells of the peripheral zone. While many cases present as slow-growing, indolent disease monitored via active surveillance, high-risk variants can be aggressive and prone to bone metastasis. Standard diagnostic pathways rely on serum prostate-specific antigen (PSA) screening, multi-parametric MRI, and transrectal ultrasound-guided biopsies for histological grading using the Gleason score.
Etiology & Risk Factors
The development of prostate adenocarcinoma is driven by a combination of non-modifiable biological factors and cumulative genetic alterations.
Primary Causes & Risk Factors:
- Age: The strongest risk factor; incidence rises sharply after age 50.
- Family History: A first-degree relative with prostate cancer doubles the risk.
Genetic Predispositions:
- Germline Mutations: Mutations in BRCA2 (and to a lesser extent BRCA1) are associated with more aggressive phenotypes and poorer outcomes.
- HOXB13: A specific mutation (G84E) is a recognized marker for hereditary prostate cancer.
- Lynch Syndrome: Men with mismatch repair gene mutations have a significantly higher lifetime risk.
Environmental & Lifestyle:
- Diet: High intake of processed fats and red meats is linked to progression, while lycopene (tomatoes) and selenium have shown mixed protective associations.
- Metabolic Health: Obesity is correlated with a higher risk of high-grade (Gleason 8-10) disease.
Clinical Manifestations
Early-stage prostate cancer is characteristically asymptomatic. Most cases are now identified via PSA (Prostate-Specific Antigen) screening before physical symptoms appear.
Early-Stage
- Often entirely silent.
- Lower Urinary Tract Symptoms (LUTS) like frequency, urgency, or nocturia are more often due to benign prostatic hyperplasia (BPH) but warrant investigation.
Advanced/Metastatic Stage
- Bone Pain: Most common in the axial skeleton (spine, pelvis, ribs) due to osteoblastic metastases.
- Urinary Obstruction: Hematuria, hematospermia, or acute urinary retention.
- Neurological Deficits: Spinal cord compression (a surgical/radiation emergency).
- Paraneoplastic Syndromes: Though rare compared to lung cancer, prostate cancer can present with Cushing Syndrome (ectopic ACTH) or Syndrome of Inappropriate Antidiuretic Hormone (SIADH), particularly in neuroendocrine variants.
Diagnostic Workup:
The diagnostic pathway has evolved to minimize over-diagnosis while maximizing the detection of “clinically significant” cancer (Gleason Grade Group ≥2).
- Screening & Risk Assessment: PSA + DRE (Digital Rectal Examination)-DRE.
- mpMRI (Multiparametric MRI):A pre-biopsy mpMRI of the Prostate is now mandatory. Results are scored using PI-RADS. A PI-RADS 4 or 5 lesion indicates a high probability of significant cancer.
- Targeted Fusion Biopsy: Perform a Transperineal / Transrectal MRI-Ultrasound Fusion Biopsy.
Common Investigations & Staging
Prostate cancer imaging relies on mpMRI for local staging and PSMA PET-CT as the gold standard for detecting lymph node and bone metastases.
- mpMRI (Abdomen/Pelvis): Best for local T-staging (extracapsular extension, seminal vesicle invasion).
- PSMA PET-CT (e.g., 68Ga-PSMA-11): The gold standard for N and M staging. It is far more sensitive than traditional bone scans or CT for detecting nodal spread and early bone metastases, even at low PSA levels (<1.0 ng/mL).
- Whole-Body MRI: Used as an alternative for monitoring bone-only disease without radiation exposure.
Treatment Overview
1. Surgery
- Robotic-Assisted Radical Prostatectomy (RARP): The standard of care. Minimal invasive approach offering better visualization for nerve-sparing techniques to preserve potency and continence.
- Nerve-Sparing: Prioritized for localized disease to maintain continence & erectile function.
2. Radiotherapy
- IMRT/VMAT: Intensity-Modulated Radiation Therapy allows high doses to the prostate while sparing the rectum and bladder.
- SBRT (Stereotactic Body Radiotherapy): Delivers ultra-hypofractionated doses in 5 sessions. Highly effective for low-to-intermediate risk disease.
- Proton Therapy: Used to reduce "integral dose" to surrounding tissues, particularly in younger patients.
3. Systemic Therapy
- Hormone Therapy (ADT): The backbone of advanced treatment using LHRH agonists (e.g., Leuprolide) or antagonists (e.g., Degarelix).
- ARPIs (Androgen Receptor Pathway Inhibitors): Abiraterone, Enzalutamide, and Darolutamide are now used earlier in both metastatic and high-risk non-metastatic settings.
- Chemotherapy: Docetaxel remains the first-line taxane for metastatic castrate-resistant prostate cancer (mCRPC).
Emerging Therapies
- Radioligand Therapy (RLT): 177Lu-PSMA-617 (Pluvicto) is now integrated into earlier lines of treatment for PSMA-positive mCRPC, delivering targeted beta-radiation directly to cancer cells.
- Antibody-Drug Conjugates (ADCs): Novel ADCs targeting STEAP1 are showing promise in patients who have exhausted ARPI and taxane options.
- AI-Driven Pathology: Deep-learning algorithms (e.g., Paige Prostate) are now used routinely to assist pathologists in grading (Gleason) and identifying sub-visual features that predict treatment response.
Medical Disclaimer
This information is intended for professional educational purposes and reflects clinical standards as of 2026.
It does not replace the professional judgment of a treating oncologist or urologist.
Treatment should be individualized based on patient comorbidities, preferences, and multi-disciplinary tumor board recommendations.